Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to stop prostate cancer spread in high-risk patients

NCT ID NCT07237269

Recruiting now Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for men with prostate cancer that has spread to pelvic lymph nodes only detectable by a special PSMA scan. It compares standard hormone therapy plus radiation to a stronger combination adding abiraterone and prednisone. The goal is to see if the stronger treatment improves 5-year survival without cancer returning. About 140 participants will be followed for 5 years after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.